



Recipient Information

1. Recipient Name

Missouri Department of Health
920 Wildwood Dr
Missouri Dept. of Health and Senior Services
Jefferson City, MO 65109-5796
[NO DATA]

2. Congressional District of Recipient

03

3. Payment System Identifier (ID)

[REDACTED]

4. Employer Identification Number (EIN)

[REDACTED]

5. Data Universal Numbering System (DUNS)

878092600

6. Recipient's Unique Entity Identifier

7. Project Director or Principal Investigator

Ms. Christine Smith
CO - Principal Investigator
christine.smith@health.mo.gov
573-751-6439

8. Authorized Official

Ms. Marcia Mahaney
Director, Division of Administration
marcia.mahaney@health.mo.gov
573-751-6014

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Terrian Dixon
Grants Management Officer
thd4@cdc.gov
770-488-2774

10. Program Official Contact Information

Mary Allen
IDJ8@cdc.gov
404-639-5200

Federal Award Information

11. Award Number

5 NU62PS924577-04-00

12. Unique Federal Award Identification Number (FAIN)

NU62PS924577

13. Statutory Authority

301(A)AND317(K)(2)PHS42USC241(A)247B(K)2

14. Federal Award Project Title

Integrated HIV Surveillance and Prevention Programs for Health Departments

15. Assistance Listing Number

93.940

16. Assistance Listing Program Title

HIV Prevention Activities_Health Department Based

17. Award Action Type

Non-Competing Continuation

18. Is the Award R&D?

No

Summary Federal Award Financial Information

| | | | |
|--|------------|------------|-----------------|
| 19. Budget Period Start Date | 01/01/2021 | - End Date | 12/31/2022 |
| 20. Total Amount of Federal Funds Obligated by this Action | | | \$1,119,372.00 |
| 20a. Direct Cost Amount | | | \$1,043,583.00 |
| 20b. Indirect Cost Amount | | | \$75,789.00 |
| 21. Authorized Carryover | | | \$0.00 |
| 22. Offset | | | \$0.00 |
| 23. Total Amount of Federal Funds Obligated this budget period | | | \$0.00 |
| 24. Total Approved Cost Sharing or Matching, where applicable | | | \$0.00 |
| 25. Total Federal and Non-Federal Approved this Budget Period | | | \$1,119,372.00 |
| 26. Project Period Start Date | 01/01/2018 | - End Date | 12/31/2022 |
| 27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period | | | \$14,551,833.00 |

28. Authorized Treatment of Program Income

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Mr. Arthur Lusby
Grants Management Officer, Team Lead

30. Remarks

Non-Competing Continuation: Financial Assistance in the amount of \$1,119,372



| Recipient Information |
|---|
| Recipient Name Missouri Department of Health 920 Wildwood Dr Missouri Dept. of Health and Senior Services Jefferson City, MO 65109-5796 [NO DATA] |
| Congressional District of Recipient 03 |
| Payment Account Number and Type [REDACTED] |
| Employer Identification Number (EIN) Data [REDACTED] |
| Universal Numbering System (DUNS) 878092600 |
| Recipient's Unique Entity Identifier Not Available |
| 31. Assistance Type Cooperative Agreement |
| 32. Type of Award Other |

| 33. Approved Budget (Excludes Direct Assistance) | |
|---|-----------------------|
| I. Financial Assistance from the Federal Awarding Agency Only | |
| II. Total project costs including grant funds and all other financial participation | |
| a. Salaries and Wages | \$232,090.00 |
| b. Fringe Benefits | \$144,967.00 |
| c. Total Personnel Costs | \$377,057.00 |
| d. Equipment | \$0.00 |
| e. Supplies | \$98,741.00 |
| f. Travel | \$18,992.00 |
| g. Construction | \$0.00 |
| h. Other | \$21,370.00 |
| i. Contractual | \$527,423.00 |
| j. TOTAL DIRECT COSTS | \$1,043,583.00 |
| k. INDIRECT COSTS | \$75,789.00 |
| l. TOTAL APPROVED BUDGET | \$1,119,372.00 |
| m. Federal Share | \$1,119,372.00 |
| n. Non-Federal Share | \$0.00 |

| 34. Accounting Classification Codes | | | | | |
|-------------------------------------|----------------|---------------------|--------------|---------------------------------|---------------|
| FY-ACCOUNT NO. | DOCUMENT NO. | ADMINISTRATIVE CODE | OBJECT CLASS | AMT ACTION FINANCIAL ASSISTANCE | APPROPRIATION |
| 0-93909SC | 18NU62PS924577 | PS | 41 51 | \$0 00 | 75-20-0950 |
| 0-93909SM | 18NU62PS924577 | PS | 41 51 | \$0 00 | 75-20-0950 |
| 9-93909SC | 18NU62PS924577 | PS | 41 51 | \$0 00 | 75-19-0950 |
| 9-93909SM | 18NU62PS924577 | PS | 41 51 | \$0 00 | 75-19-0950 |
| 1-93909SC | 18NU62PS924577 | PS | 41 51 | \$935,022 00 | 75-21-0950 |
| 1-93909SM | 18NU62PS924577 | PS | 41 51 | \$184,350 00 | 75-21-0950 |



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 5 NU62PS924577-04-00

FAIN# NU62PS924577

Federal Award Date: 12/17/2020

Direct Assistance

| BUDGET CATEGORIES | PREVIOUS AMOUNT (A) | AMOUNT THIS ACTION (B) | TOTAL (A + B) |
|-------------------|---------------------|------------------------|---------------|
| Personnel | \$0.00 | \$0.00 | \$0.00 |
| Fringe Benefits | \$0.00 | \$0.00 | \$0.00 |
| Travel | \$0.00 | \$0.00 | \$0.00 |
| Equipment | \$0.00 | \$0.00 | \$0.00 |
| Supplies | \$0.00 | \$0.00 | \$0.00 |
| Contractual | \$0.00 | \$0.00 | \$0.00 |
| Construction | \$0.00 | \$0.00 | \$0.00 |
| Other | \$0.00 | \$0.00 | \$0.00 |
| Total | \$0.00 | \$0.00 | \$0.00 |



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 5 NU62PS924577-04-00

FAIN# NU62PS924577

Federal Award Date: 12/17/2020

35. Terms And Conditions

| Federal Financial Report Cycle | | | |
|--------------------------------|---------------------------|----------------|---------------------------|
| Reporting Period Start Date | Reporting Period End Date | Reporting Type | Reporting Period Due Date |
| 01/01/2018 | 12/31/2018 | Annual | 03/31/2019 |
| 01/01/2019 | 12/31/2019 | Annual | 09/06/2020 |
| 01/01/2021 | 12/31/2021 | Annual | 03/31/2022 |
| 01/01/2022 | 12/31/2022 | Annual | 03/31/2023 |

AWARD ATTACHMENTS

Missouri Department of Health

5 NU62PS924577-04-00

1. YEAR 04 TERMS AND CONDITIONS PS18 1802

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number **CDC-RFA-PS18-1802**, entitled **Integrated HIV Surveillance and Prevention Programs for Health Departments, National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)**, and application dated **September 11, 2020**, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Approved Funding: Funding in the amount of **\$4,477,487** is approved for the Year **04** budget period, which is **January 1, 2021** through **December 31, 2021**. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third party in-kind contribution when applicable.

Available Funding: The CDC is operating under a continuing resolution; as a result, the total available funding for the Fiscal Year (FY) 04 budget period is contingent upon the enactment of applicable appropriation bill(s). Funding in the amount of **\$1,119,372** in Financial Assistance (FA) is awarded on this NoA. The remainder of the budget period Approved Funding amount is subject to the availability of funds.

| Component Funding | Amount |
|----------------------------------|-------------------|
| Component A: Surveillance | \$ 184,350 |
| Component A: Prevention | \$ 935,022 |

Note: Refer to the Payment Information section for draw down and Payment Management System (PMS) subaccount information.

Financial Assistance Mechanism: Cooperative Agreement

Substantial Involvement by CDC: This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

In a cooperative agreement, CDC staff are substantially involved in the program activities, above and beyond routine grant monitoring. CDC activities for this program are as follows:

1. Collaborate to ensure coordination and implementation of strategies to support the implementation of HIV surveillance and prevention activities.

2. Work with awardees to identify and address capacity building assistance (CBA) and TA needs that are essential to the success of the project. Awardees must work with the assigned Project Officer/Project Consultant/Epidemiologist to establish a mechanism to request direct CDC TA and establish a CBA Request Information System (CRIS) user account to facilitate receipt of CBA.
3. Provide access to training and TA that will strengthen staff capacity relevant to all required strategies and activities of the program.
4. Provide guidance to awardees and set standards on data collection, use, and submission requirements.
5. Facilitate coordination, collaboration, and, where feasible, service integration among federal agencies, other CDC funded programs, other health departments, community based organizations, local and state planning groups, other CDC directly funded programs, national capacity building assistance providers, medical care providers, laboratories, recipients of the Ryan White HIV/AIDS Treatment Extension Act of 2009, and other partners working with people living with and at greatest risk for HIV infection toward common goals of risk reduction, disease detection, and a continuum of HIV prevention, care, and treatment.
6. Monitor awardee program performance using multiple approaches, such as site visits, emails, conference calls, and standardized review of performance, grantee feedback and other data reports, to support program development, implementation, evaluation, and improvement.
7. Provide guidance and coordination to funded organizations to improve the quality and effectiveness of work plans, evaluation strategies, products and services, and collaborative activities with other organizations.
8. Collaborate to compile and publish accomplishments, best practices, performance criteria, and lessons learned during the project period.
9. Collaborate in assessing progress toward meeting strategic and operational goals/objectives and in establishing measurement and accountability systems for 37 of 77 documenting outcomes, such as increased performance improvements and best or promising practices.
10. Collaborate on strategies to ensure the provision of appropriate and effective HIV prevention services to target populations.
11. Provide requirements and expectations for standardized and other data reporting and support monitoring and evaluation activities.
12. Share information, best practices, lessons learned, and evaluation results between awardees (e.g., through conferences, guidance, material development, webinars, data sharing publications, other social media, participation in meetings, committees, conference calls, and working groups related to the cooperative agreement and its projects).

Budget Revision Requirement: By **February 01, 2021** the recipient must submit a revised budget with a narrative justification. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the CDC Staff Contacts section of this notice before the due date.

Surveillance Budget

Personnel:

1. Funds were requested to support two positions identified as vacant. Grant funds must match the effort. To fund the positions for a proposed 12 months would be considered forward funding and would therefore lead to an unobligated balance. Please notify OGS if the position has been filled since the submission of the application. If the position remains vacant please notify OGS of the anticipated start date.

Prevention Budget

Personnel:

1. Funds were requested to support several positions identified as vacant. Grant funds must match the effort. To fund the positions for a proposed 12 months would be considered forward funding and would therefore lead to an unobligated balance. Please notify OGS if the position has been filled since the submission of the application. If the position remains vacant please notify OGS of the anticipated start date.

Travel (In and Out of State):

2. Under the "Travel" cost category for each In State or Out of State travel, provide name or position(s) of who will be traveling for **each** individual trip.

Expanded Authority: The recipient is permitted the following expanded authority in the administration of the award.

- Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. Recipients will report use, or intended use, of unobligated funds in Section 12 "Remarks" of the annual Federal Financial Report. If the GMO determines that some or all of the unobligated funds are not necessary to complete the project, the GMO may restrict the recipient's authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset CDC funding for a subsequent budget period, or use a combination of these actions.

Program Income: Addition alternative: Under this alternative, program income is added to the funds committed to the project/program and is used to further eligible project/program objectives.

Note: *The disposition of program income must have written prior approval from the GMO.*

FUNDING RESTRICTIONS AND LIMITATIONS

Notice of Funding Opportunity (NOFO) Restrictions:

Restrictions that must be considered while planning the programs and writing the budget are:

- Recipients may not use funds for research.
- Recipients may not use funds for clinical care except as allowed by law.

- Recipients may use funds only for reasonable program purposes, including personnel, travel, supplies, and services.
- Generally, recipients may not use funds to purchase furniture or equipment. Any such proposed spending must be clearly identified in the budget.
- Reimbursement of pre-award costs generally is not allowed, unless the CDC provides written approval to the recipient.
- Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - the salary or expenses of any cooperative agreement or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body.
- See [Additional Requirement \(AR\) 12](http://www.cdc.gov/grants/additionalrequirements/index.html#ar12) (<http://www.cdc.gov/grants/additionalrequirements/index.html#ar12>) for detailed guidance on this prohibition and [additional guidance on lobbying for CDC recipients](http://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf) (http://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf).
 - The direct and primary recipient in a cooperative agreement program must perform a substantial role in carrying out project outcomes and not merely serve as a conduit for an award to another party or provider who is ineligible.
- Awardees may not use funds to purchase antiretroviral therapy.
- Awardees may not use funds to purchase sterile needles or syringes for drug injection.
 - Funding should not be used for construction purposes.

Indirect Costs: Indirect costs are approved based on the Indirect Cost Rate Agreement dated **March 17, 2020**, which calculates indirect costs as follows: The type is **FIXED** with an effective period of **07/01/20 to 06/30/21** at a rate of **20.10** percent for **On Site** locations, applicable to **All Programs**.

Base: Direct salaries and wages including all fringe benefits.

REPORTING REQUIREMENTS

Annual Federal Financial Report (FFR, SF-425): The Annual Federal Financial Report (FFR) SF-425 is required and must be submitted to **Payment Management System** no later than 90 days after the end of the budget period. The FFR for this budget period is due by **March 31, 2022**. Reporting timeframe is **January 1, 2021** through **December 31, 2021**. The FFR should only include those funds authorized and disbursed during the timeframe covered by the report.

Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, the

recipient is required to contact the Grants Officer listed in the contacts section of this notice before the due date.

Additional guidance on submission of Federal Financial Reports can be found at <https://www.cdc.gov/grants/documents/change-in-federal-reporting-fy-2021-recipient.pdf>.

Annual Performance Progress Reporting: The Annual Performance Progress and Monitoring Report (is due no later than 120 days prior to the end of the budget period, **September 02, 2021**, and serves as the continuation application for the follow-on budget period. This report should include the information specified in the solicitation from the GMS/GMO via www.grantsolutions.gov .

Performance Progress and Monitoring: Performance information collection initiated under this grant/cooperative agreement has been approved by the Office of Management and Budget under **OMB Number 0920-1132, "Performance Progress and Monitoring Report", Expiration Date 10/31/2022** The components of the PPMR are available for download at: <https://www.cdc.gov/grants/alreadyhavegrant/Reporting.html> .

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services

Terrian J. Dixon, Grants Management Officer/Specialist
Centers for Disease Control and Prevention
Prevention Infectious Disease Services
2939 Flowers Road, MS TV-2
Atlanta, GA 30341
Email: Tdixon@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or
Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PROGRAM OR FUNDING GENERAL REQUIREMENTS

HIV Program Review Panel Requirement: All written materials, audiovisual materials, pictorials, questionnaires, survey instruments, websites, educational curricula and other relevant program materials must be reviewed and approved by an established program review panel. A list of reviewed materials and approval dates must be submitted to the CDC Grants Management Specialist identified in the CDC Roles and Responsibilities section of this NoA.

Prior Approval: All requests, which require prior approval, must bear the signature of the authorized organization representative. The recipient must submit these requests by **September 02, 2021**. Additionally, any requests involving funding issues must include an itemized budget and a narrative justification of the request.

The following types of requests require prior approval:

- Lift funding restriction
- Significant redirection of funds (i.e. cumulative changes of 25% of total award)
- Change in scope
- Implement a new activity or enter into a sub-award that is not specified in the approved budget
- Apply for supplemental funds
- Change in key personnel
- Extensions to period of performance

Templates for prior approval requests can be found at:

<http://www.cdc.gov/grants/alreadyhavegrant/priorapprovalrequests.html>

Templates for prior approval requests can be found at:

[http://www.cdc.gov/grants/alreadyhavegrant/priorapprovalrequests.h
tml.](http://www.cdc.gov/grants/alreadyhavegrant/priorapprovalrequests.html)

Additional information on the electronic grants administration system CDC non-research awards utilize, Grants Solutions, can be found at:

<https://www.cdc.gov/grants/grantsolutions/index.html>.

Key Personnel: In accordance with 45 CFR Part 75.308, CDC recipients must obtain prior approval from CDC for (1) change in the project director/principal investigator, business official, authorized organizational representative or other key persons

specified in the NOFO, application or award document; and (2) the disengagement from the project for more than three months, or a 25 percent reduction in time devoted to the project, by the approved Project Director or Principal Investigator.

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the “**P Account**”. Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on page 2, item 34 of the Notice of Award must be known in order to draw down funds.

CDC Staff Contacts Information is listed on page 1 of the NoA

Grants Management Specialist: The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

Program/Project Officer: The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

Grants Management Officer: The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.